Ventracor chalks up first revenues

By Ruth Beran
Tuesday, 20 September, 2005

Ventracor (ASX:VCR) has received its first revenues, in the form of a cheque from the University of Maryland Medical Centre as payment for a VentrAssist left ventricular assist device (LVAD) recently implanted in a patient as part of its US clinical trial.

The company previously indicated it would reach the milestone before the end of 2005.

Babies of stressed mothers likely to get their teeth earlier

Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...

Customised immune cells used to fight brain cancer

Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...

Elevated blood protein levels predict mortality

Proteins that play key roles in the development of diseases such as cancer and inflammation may...

Content from other channels on our network

Defence Trailblazer funding manufacturing to help Defence and industry transition to clean energy

Fitzroy River Water chooses Honeywell SCADA

Titomic announces breakthrough in lithium‍-‍ion electrode manufacturing

Advantech signs Centralian Controls as channel partner

Lockheed Martin opens missile assembly facility in SA

ASC certifies NT barramundi farm

NiCE advances ESG leadership

ARBS 2026 returns to Melbourne in May

First nature-related financial disclosure for university

Calls for efficiency standards for data centre water use

Helping to keep health care professionals hands-on

Fundamental reimagining: new Sydney Children's Hospital, Randwick

A Day in the Life of a health equity consultant and street health nurse

$1bn vaccine and antivenom manufacturing facility opens

In Conversation with Australasian Institute of Digital Health CEO Anja Nikolic